» Articles » PMID: 7792729

Definition of the Bleeding Tendency in Factor XI-deficient Kindreds--a Clinical and Laboratory Study

Overview
Journal Thromb Haemost
Publisher Thieme
Date 1995 Feb 1
PMID 7792729
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Individuals with severe factor XI deficiency are prone to excessive bleeding after injury or surgery, but the existence of a haemorrhagic tendency in partial factor XI deficiency is controversial. In this study, 172 members of 30 kindreds (20 non-Jewish) transmitting factor XI deficiency in North West England were interviewed and a bleeding history questionnaire completed. Blood was taken for coagulation assays. The questionnaires were categorised independently by two assessors to determine presence or absence of a bleeding tendency, in the absence of information about the factor XI level or family history. Analysis shows that 48% of heterozygotes have a bleeding tendency. Eighteen (60%) families came to attention because of bleeding problems in heterozygotes. Comparison of histories between partially deficient and non-deficient individuals demonstrated a higher incidence of menstrual problems, an increase in significant bruising, and an increased likelihood of excessive bleeding after tonsillectomy and dental extractions. The incidence of von Willebrand's disease was not increased, but individuals with heterozygous factor XI deficiency who were bleeders tended to have lower levels of factor VIIIc and von Willebrand factor, and were more commonly of blood group 0. These features may contribute to the bleeding tendency. There was no evidence of alteration in factor VII activity (as defined by the ratio of activity to antigen) between the bleeders and non-bleeders. This is convincing evidence for abnormal bleeding in factor XI deficiency which is not confined to severely deficient patients.

Citing Articles

The factor XI/XIa antibody abelacimab combined with enoxaparin inhibits filter clotting in hemodialysis circuits ex vivo.

Grafeneder J, Langer G, Schoergenhofer C, Eskandary F, Jilma B, Khder Y J Thromb Thrombolysis. 2024; 57(8):1339-1348.

PMID: 39549166 PMC: 11645315. DOI: 10.1007/s11239-024-03059-x.


Laboratory and Molecular Diagnosis of Factor XI Deficiency.

Davidson S, Gomez K Semin Thromb Hemost. 2024; 51(2):145-154.

PMID: 39496302 PMC: 11906224. DOI: 10.1055/s-0044-1792033.


Targeting factor XI and factor XIa to prevent thrombosis.

Gailani D, Gruber A Blood. 2023; 143(15):1465-1475.

PMID: 38142404 PMC: 11033593. DOI: 10.1182/blood.2023020722.


Tissue factor pathway inhibitor is a potential modifier of bleeding risk in factor XI deficiency.

Reitsma S, Holle L, Bouck E, Monroe D, Mast A, Burthem J J Thromb Haemost. 2023; 21(3):467-479.

PMID: 36696199 PMC: 10111213. DOI: 10.1016/j.jtha.2022.10.005.


Obstetric and perioperative management of patients with factor XI deficiency: a retrospective observational study.

Handa S, Sterpi M, Sacchi de Camargo Correia G, Frankel D, Beilin Y, Cytryn L Blood Adv. 2022; 7(10):1967-1975.

PMID: 36521104 PMC: 10189368. DOI: 10.1182/bloodadvances.2022008648.